PHS Act Section 351 - Biologics Licensing

What it says

Section 351 of the Public Health Service Act establishes the licensing framework for biological products, requiring a Biologics License Application demonstrating the product is safe, pure and potent, with licensure covering both the product and, distinctively, the specific establishment where it is manufactured.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Biologics licensure under this framework is distinct from the New Drug Application pathway under FD&C Act Section 505, reflecting biological products' unique manufacturing complexity and the historical regulatory approach treating biologics licensing and facility licensing as closely linked.
• Because licensure is tied to the specific manufacturing establishment, changes to manufacturing location or, in some cases, significant process changes can carry more direct regulatory consequence for biologics than analogous changes might for a small-molecule drug under an NDA.
• The safety, purity and potency standard reflects biologics-specific considerations, purity in particular addressing the presence of extraneous material distinct from the product itself, a consideration with particular relevance given biological products' complex source materials and manufacturing processes.

What FDA inspectors look for

• This is a foundational statutory licensing framework rather than a specific manufacturing practice - its practical relevance is that manufacturing changes, particularly involving the licensed establishment itself, must be properly assessed against licensure requirements before implementation.
• Whether current manufacturing practices at a licensed establishment continue to match what was described and approved as part of the original biologics license application.

Related regulations